Original Articles

You have full text access to this OnlineOpen article

Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease

  1. Jacqueline G. O'Leary†,*,
  2. Gary L. Davis

Article first published online: 29 SEP 2009

DOI: 10.1002/lt.21836

Issue

Liver Transplantation

Liver Transplantation

Volume 15, Issue 10, pages 1325–1329, October 2009

Additional Information

How to Cite

O'Leary, J. G. and Davis, G. L. (2009), Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl, 15: 1325–1329. doi: 10.1002/lt.21836

Author Information

  1. Division of Hepatology, Department of Medicine, Baylor University Medical Center, Dallas, TX

  1. †

    Telephone: 214-820-8500; FAX: 214-820-8168

*Baylor University Medical Center, 4th Floor Roberts Building, 3500 Gaston Avenue, Dallas, TX 75246

Publication History

  1. Issue published online: 29 SEP 2009
  2. Article first published online: 29 SEP 2009
  3. Manuscript Accepted: 11 MAY 2009
  4. Manuscript Received: 18 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (165K)

REFERENCES

  • 1
    Londono MC, Cardenas A, Guevara M, Quinto L, de Las Heras D, Navasa M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56: 1283–1290.
  • 2
    Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018–1026.
  • 3
    Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802–810.
  • 4
    Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336–343.
    Direct Link:
  • 5
    Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91–96.
  • 6
    Londono MC, Guevara M, Rimola A, Navasa M, Taura P, Mas A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130: 1135–1143.
  • 7
    Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007; 13: 1115–1124.
    Direct Link:
  • 8
    Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM. Central nervous system complications in liver transplant recipients—incidence, timing, and long-term follow-up. Clin Transplant 2000; 14: 1–7.
    Direct Link:
  • 9
    DeVita MV, Gardenswartz MH, Konecky A, Zabetakis PM. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol 1990; 34: 163–166.
  • 10
    Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002–1010.
    Direct Link:
  • 11
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099–2112.
  • 12
    Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008; 48: 204–213.
    Direct Link:
  • 13
    Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197–1205.
    Direct Link:
  • 14
    Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933–939.
  • 15
    Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182–191.
    Direct Link:
  • 16
    Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63: 561–570.
  • 17
    Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, et al. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther 2006; 24: 973–982.
    Direct Link:
  • 18
    Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851–864.
    Direct Link:
  • 19
    Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44: 1535–1542.
    Direct Link:
View Full Article (HTML) Get PDF (165K)